Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SELL | P14151 | 2/20 | 0.48 |
| ▸ | SELP | P16109 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SELE | P16581 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7772145 | 0.79 | AKR1C3 (0.54) | AKR1C3L3MBTL1SELLSELPALDH1A1 | |
| SCHEMBL27286217 | 0.79 | ALDH1A1 (0.64) | L3MBTL1ALDH1A1KDM4ECASRNPC1 | |
| SCHEMBL27347830 | 0.79 | HDAC1 (0.44) | L3MBTL1ALDH1A1KDM4ENPC1MAPT | |
| SCHEMBL4012969 | 0.78 | ALDH1A1 (0.62) | AKR1C3L3MBTL1SELLSELPALDH1A1 | |
| SCHEMBL26292488 | 0.78 | AKR1C3 (0.53) | AKR1C3L3MBTL1SELLSELPALDH1A1 | |
| SCHEMBL560143 | 0.76 | L3MBTL1 (0.57) | L3MBTL1SELLSELPALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL1416836 | 0.76 | ALDH1A1 (0.61) | AKR1C3L3MBTL1SELLSELPALDH1A1 | |
| SCHEMBL24003733 | 0.75 | RAB9A (0.46) | L3MBTL1ALDH1A1KDM4ENPC1MAPT | |
| SCHEMBL11982549 | 0.75 | ALDH1A1 (0.50) | AKR1C3L3MBTL1SELLSELPALDH1A1 | |
| SCHEMBL13073785 | 0.75 | KDM4E (0.63) | AKR1C3L3MBTL1SELLSELPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020017934-A1 | COLORED CURABLE RESIN COMPOSITION, COLOR FILTER, AND DISPLAY APPARATUS | 동우 화인켐 주식회사 | 2020-01-23 | — | — | WO | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| EP-1742105-A2 | Photothermographic material | Fuji Photo Film Co., Ltd. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | AKR1C3 667/4885L3MBTL1 4658/4885SELL 2530/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | AKR1C3 1475/4885L3MBTL1 3351/4885SELL 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.